IGF1 and neoplasm: These findings suggest that at high IGF-TRAP-3.3 doses, a feedback loop resulting in increased IGF-1 production may have resulted in the loss of added therapeutic benefit and that the difference in IGF bioavailability in the first 4 days post tumor injections had profound effects on outcome.